CU24718B1 - Nuevas formulaciones de comprimido de fosfomicina - Google Patents
Nuevas formulaciones de comprimido de fosfomicinaInfo
- Publication number
- CU24718B1 CU24718B1 CU2022000009A CU20220009A CU24718B1 CU 24718 B1 CU24718 B1 CU 24718B1 CU 2022000009 A CU2022000009 A CU 2022000009A CU 20220009 A CU20220009 A CU 20220009A CU 24718 B1 CU24718 B1 CU 24718B1
- Authority
- CU
- Cuba
- Prior art keywords
- fosphomycin
- new
- tablet formulations
- relates
- tablet
- Prior art date
Links
- 239000007916 tablet composition Substances 0.000 title abstract 2
- YMZJBJPWTXJQMR-UHFFFAOYSA-L calcium;(3-methyloxiran-2-yl)-dioxido-oxo-$l^{5}-phosphane Chemical compound [Ca+2].CC1OC1P([O-])([O-])=O YMZJBJPWTXJQMR-UHFFFAOYSA-L 0.000 title 1
- 229960000308 fosfomycin Drugs 0.000 abstract 2
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 abstract 1
- 235000019700 dicalcium phosphate Nutrition 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
<p>La presente invención se refiere a formulaciones de comprimido de fosfomicina trometamol y a métodos de fabricación de las mismas. Más específicamente, se refiere a una composición farmacéutica oral en forma de comprimido que comprende:</p> <p>a. fosfomicina trometamol;</p> <p>b. hidrogenofosfato de calcio anhidro; y</p> <p>c. celulosa microcristalina anhidra.</p> <p> </p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382104 | 2021-02-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20220009A7 CU20220009A7 (es) | 2023-09-07 |
| CU24718B1 true CU24718B1 (es) | 2024-08-15 |
Family
ID=74732835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2022000009A CU24718B1 (es) | 2021-02-10 | 2022-02-04 | Nuevas formulaciones de comprimido de fosfomicina |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11833250B2 (es) |
| EP (1) | EP4043006B1 (es) |
| AR (1) | AR124833A1 (es) |
| BR (1) | BR102022002475A2 (es) |
| CA (1) | CA3147662A1 (es) |
| CO (1) | CO2022001244A1 (es) |
| CU (1) | CU24718B1 (es) |
| ES (1) | ES2970581T3 (es) |
| MX (1) | MX2022001746A (es) |
| PE (1) | PE20221446A1 (es) |
| TW (1) | TW202245740A (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20021725A1 (it) | 2002-08-01 | 2002-10-31 | Zambon Spa | Composizioni farmaceutiche ad attivita' antibiotica. |
| ES2244333B1 (es) | 2004-05-18 | 2006-08-01 | Simbec Iberica, Sl | Preparado farmaceutico oral de fosfomicina estable y apto para diabeticos. |
| TW201129386A (en) | 2009-11-05 | 2011-09-01 | Fmc Corp | Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients |
| ES2385158B1 (es) | 2010-12-24 | 2013-05-28 | Arafarma Group, S.A. | Composición farmacéutica de fosfomicina |
| US8604078B2 (en) | 2011-04-06 | 2013-12-10 | Carlos Picornell Darder | Fosfomycin pharmaceutical composition |
-
2022
- 2022-02-03 CA CA3147662A patent/CA3147662A1/en active Pending
- 2022-02-04 CU CU2022000009A patent/CU24718B1/es unknown
- 2022-02-08 AR ARP220100248A patent/AR124833A1/es unknown
- 2022-02-08 CO CONC2022/0001244A patent/CO2022001244A1/es unknown
- 2022-02-09 BR BR102022002475-8A patent/BR102022002475A2/pt unknown
- 2022-02-09 MX MX2022001746A patent/MX2022001746A/es unknown
- 2022-02-09 US US17/668,146 patent/US11833250B2/en active Active
- 2022-02-09 PE PE2022000222A patent/PE20221446A1/es unknown
- 2022-02-10 TW TW111104960A patent/TW202245740A/zh unknown
- 2022-02-10 ES ES22156013T patent/ES2970581T3/es active Active
- 2022-02-10 EP EP22156013.9A patent/EP4043006B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AR124833A1 (es) | 2023-05-10 |
| TW202245740A (zh) | 2022-12-01 |
| ES2970581T3 (es) | 2024-05-29 |
| US20220387329A1 (en) | 2022-12-08 |
| BR102022002475A2 (pt) | 2022-08-23 |
| CA3147662A1 (en) | 2022-08-10 |
| EP4043006A1 (en) | 2022-08-17 |
| US11833250B2 (en) | 2023-12-05 |
| PE20221446A1 (es) | 2022-09-21 |
| EP4043006B1 (en) | 2023-12-06 |
| CU20220009A7 (es) | 2023-09-07 |
| CO2022001244A1 (es) | 2023-02-16 |
| MX2022001746A (es) | 2022-08-11 |
| EP4043006C0 (en) | 2023-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123549T1 (el) | Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης | |
| ECSP066376A (es) | FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN | |
| CL2017003445A1 (es) | Formas solidas y formulaciones de compuestos de imidazopirazina. | |
| ECSP066375A (es) | Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen | |
| NI200600240A (es) | FORMA CRISTALINA Delta-d CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN, Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN | |
| GT200600200A (es) | Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato | |
| BRPI0908052A2 (pt) | Composições farmacêuticas de entacapone, levodopa e carbidopa com biodisponibilidade melhorada | |
| CO6351689A2 (es) | Formulaciones farmaceuticas que contienen ligandos de receptores de dopamina | |
| UY39390A (es) | Forma amorfa de un inhibidor de la malt1 y formulaciones del mismo | |
| CY1114190T1 (el) | Νεα μορφη χορηγησης της ρασεκαδοτριλης | |
| EA201890193A1 (ru) | Композиция для ухода за полостью рта | |
| AR067140A2 (es) | Nuevo procedimiento de tratamiento de frutas o legumbres mediante el ion fosforoso y las composiciones correspondientes | |
| CL2015000869A1 (es) | Composiciones para el cuidado bucal. | |
| EA201071183A1 (ru) | Безводная кристаллическая форма малеата орвепитанта | |
| BR122016006880B8 (pt) | forma de dosagem contendo pantoprazol como ingrediente ativo | |
| CU24718B1 (es) | Nuevas formulaciones de comprimido de fosfomicina | |
| EA200901591A1 (ru) | Фармацевтические композиции производных s-алкилизотиоурония с маскированным вкусом | |
| DK1531831T3 (da) | Fosinoprilformulering | |
| CL2008002828A1 (es) | Tableta oral que comprende una cantidad mayor de 38% de alisquireno o una de sus sales y fosfato acido de calcio como relleno. | |
| ECSP13013043A (es) | Composición oral líquida que comprende sodio divalproex y proceso para preparar la misma | |
| DOP2011000194A (es) | Formulaciones de desintegracion rapida pre-compactadas de compuestos con baja biodisponibilidad oral | |
| CL2020002407A1 (es) | Composición farmacéutica y método de fabricación | |
| CR20220449A (es) | Composiciones farmacéuticas de sales de éster de colina de ácido lipoico y métodos de tratamiento usando las mismas | |
| CO2022000503A2 (es) | Composiciones sólidas orales de liberación inmediata de múltiples unidades, métodos y usos de las mismas | |
| EA201190243A1 (ru) | Стабильная фармацевтическая композиция флударабина фосфата |